Table 1 Patient characteristics
Early RA | HC | ||||
|---|---|---|---|---|---|
(n = 152) | (n = 88) | ||||
Time after treatment initiation (months) | 0 | 6 | 12 | 24 | |
Age (years) | 56 (43–63) | – | – | – | 53 (46–61) |
Gender (% female) | 69 | – | – | – | 68 |
Baseline characteristics | |||||
Disease duration (days) | 84 (43–130) | – | – | – | – |
IgM-RF (% positive) | 71 | – | – | – | – |
Anti-CCP antibody (% positive) | 65 | – | – | – | – |
Treated with adalimumab (%) | 50 | – | – | – | – |
Disease activity | |||||
HAQ (0–3) | 1.1 (0.8–1.8) | 0.1 (0–0.6) | 0.1 (0–0.5) | 0.1 (0–0.5) | – |
DAS28CRP (0–10) | 5.6 (4.9–6.3) | 2.4 (1.8–3.0) | 2.0 (1.8–2.8) | 2.0 (1.8–2.7) | – |
Radiographic progression | |||||
Total Sharp score (% progressors) | – | 32 | 41 | 48 | – |